Latest Corporate News

Morris Goodman Community Partnership Day: special edition for the 35th anniversary

On September 14th, Pharmascience held for the eighth year in a row, their Community Partnership Day. Launched in 2011, in honour of the company?s co-founder, Morris Goodman, this volunteer initiative has been a success year after year.

 

GLATECT(TM) is now covered by five provincial drug plans

GLATECTTM (glatiramer acetate injection, 20 mg/1 mL) is now the only glatiramer-based treatment covered by five provincial drug plans for patients new to glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS) GLATECT(TM) is now covered for all patients new to glatiramer acetate by the provincial drug plans in Quebec, Alberta, Saskatchewan, Manitoba and New Brunswick, based on specific criteria for the treatment of relapsing-remitting multiple sclerosis (RRMS). GLATECT(TM) is the first subsequent glatiramer-based treatment to the original glatiramer acetate (COPAXONE®). GLATECTTM becomes the first subsequent glatiramer-based treatment in Multiple Sclerosis (MS) available for reimbursement under Canadian public drug plans.

 

The Pharmascience Team met the Enbridge Ride to Conquer Cancer Challenge and raised funds to advance cancer research